All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

News

Article

January 9, 2017

Amgen Links with Immatics to Continue Work on Bispecific T-Cell Therapies

Author(s):

Randi Hernandez

The companies will combine expertise on T-cell therapies with two or more binding domains to create novel oncology medications.

Amgen announced on Jan. 9, 2017 that it will partner with Immatics in the discovery of novel immunotherapy candidates based on bispecific T-cell receptor technology. Immatics’ XPRESIDENT technology recognizes tumor-specific peptide antigens, and Amgen plans to use this information coupled with its own bispecific T-cell engager (BiTE) technology to create T-cell-based therapies specific to tumors.

Both Immatics' TCR-bispecifics and Amgen’s antibody constructs recognize two or more binding domains. One domain is typically on the surface of a cancer cell via a T-cell antigen-specific receptor (TCR), and another is designed to recognize a T-cell activator, such as a T-cell stimulator CD3. These signals typically result in the clonal expansion of T-cells, differentiation into effector cells, cytotoxicity, and then cell death of the tumor cell.

Amgen already has a bispecific antibody drug on the market, so it is familiar with pushing this class of drug through the regulatory process. Amgen’s Blincyto (blinatumomab) is an antibody contruct for the treatment of refractory B-cell precursor acute lymphoblastic leukemia (ALL) and it was approved in the United States under an accelerated approval pathway. Blincyto targets cell surface proteins CD19 and CD3 simultaneously, helping to bring T cells to the cancerous cells.

Amgen will give Immatics an upfront fee of $30 million and Immatics will be eligible to receive milestone payments and royalties of more than $500 million. In 2015, Amgen entered into a similar research collaboration with Xencor for $45 million to license Xencor’s XmAb bispecific technology platform for the development of a total of six targets.

Source: Amgen

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
Understanding the Operational Impacts of the 15% US-EU Pharma Tariff Cap
Dave Miller, PhD, Chief Scientific Officer, AustinPx
Related Content
Advertisement
B. Braun - german medical technology company, Czech branch | Image Credit: © Solarisys - stock.adobe.com
August 22nd 2025

B. Braun Medical Voluntarily Recalls Two Injections, Citing Presence of Particulate Matter

Patrick Lavery
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
August 22nd 2025

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
August 22nd 2025

Johnson & Johnson Invests $2 Billion into North Carolina Facility

Susan Haigney
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
August 22nd 2025

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Bio/Pharma's Tariff Response: Key Insights from Industry Survey Results
August 22nd 2025

Bio/Pharma's Tariff Response: Key Insights from Industry Survey Results

Christopher Cole
Mitragyna speciosa or kratom leaves with medicinal products in capsules and powder in white ceramic bowl and wooden table, top view | Image Credit: ©Yanawut Suntornkij - stock.adobe.com
August 22nd 2025

Kratom and the Impact of 7-OH Reclassification

Susan Haigney
Related Content
Advertisement
B. Braun - german medical technology company, Czech branch | Image Credit: © Solarisys - stock.adobe.com
August 22nd 2025

B. Braun Medical Voluntarily Recalls Two Injections, Citing Presence of Particulate Matter

Patrick Lavery
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
August 22nd 2025

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
August 22nd 2025

Johnson & Johnson Invests $2 Billion into North Carolina Facility

Susan Haigney
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
August 22nd 2025

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Bio/Pharma's Tariff Response: Key Insights from Industry Survey Results
August 22nd 2025

Bio/Pharma's Tariff Response: Key Insights from Industry Survey Results

Christopher Cole
Mitragyna speciosa or kratom leaves with medicinal products in capsules and powder in white ceramic bowl and wooden table, top view | Image Credit: ©Yanawut Suntornkij - stock.adobe.com
August 22nd 2025

Kratom and the Impact of 7-OH Reclassification

Susan Haigney
About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.